Conversely, validation studies in RA patients, regardless of the autoimmune profile, found that variation in IHC score of sublining CD68+ cells is a valuable synovial biomarker mirroring the treatment response to conventional and biological DMARDs (rituximab and TNF inhibitor) [37–39]. This evidence concerns the gene CD68 and rheumatoid arthritis.